Fox Chase Cancer Center’s In Vino Vita gala has raised more than $12 million to support innovative cancer research, patient-centered care, and cutting-edge equipment.

This event has funded 12 pilot research grants for young investigators to propel new and innovative ideas forward; a state-of-the-art immunotherapy laboratory; sophisticated technology and equipment to enhance clinical care; 45 modern recliners for infusion room patients; established The Marian and Emma Brungard Surgical Family Waiting Suite; helped secure a second generation Mobile Screening Unit; funded a Nursing Simulation and Innovation Lab; and helped ensure the establishment of our Advanced Treatment Center.

This year’s special pledge will support Clinical Research.

With our strong bench-to-bedside model, Fox Chase is especially well positioned to bring new therapies to patients via clinical trials. We bring leading edge ideas from our
labs and compassionate expertise from our physicians and nurses together with selfless
patients to develop and test new cancer therapies.

Clinical research at Fox Chase leads to improved treatment approaches, new drugs
and targets, and bringing new ideas directly to patients in treatment. Our patients often
receive access to these therapies years before they are widely available.
Over the years, clinical research conducted at Fox Chase has contributed essential
insights that paved the way for many therapies that are now standard of care.

With your investment, Fox Chase will be able to expand our portfolio of some 300
clinical trials, so more patients get more options, outcomes improve, and new
treatments can reach more people sooner. We will also increase access to clinical trials
for patients of all backgrounds. This is as important for science as it is for equity.